Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
353 results about "Antibody targeting" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibody Targeting Targeting requires the targeting agent to have good selectivity in order to achieve efficient targeting. Antibodies bind to their targets with high specificity and binding efficiency and this makes them ideal candidates for targeted drug delivery. However, this requires the identification...
Methods and apparatus for pathogen detection and analysis
Methods and apparatus for implementing microfluidic analysis devices are provided. A monolithic elastomer membrane associated with an integrated pneumatic manifold allows the placement and actuation of dense arrays of a variety of fluid control structures, such as structures for isolating, routing, merging, splitting, and storing volumes of fluid. The fluid control structures can be used to implement a pathogen detection and analysis system including integrated immunoaffinity capture and analysis, such as polymerase chain reaction (PCR) and capillary electrophoresis (CE) analysis. An analyte solution can be input into the device and pumped through a series of immunoaffinity capture matrices in microfabricated chambers having antibodies targeted to the various classes of microbiological organisms such as bacteria, viruses and bacterial spores. The immunoaffinity chambers can capture, purify, and concentrate the target for further analysis steps.
Owner:RGT UNIV OF CALIFORNIA
Compositions and methods for antibodies targeting complement protein C5
The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
Owner:HIREVUE +1
Compositions and Methods for Antibodies Targeting Complement Protein C5
The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
Owner:HIREVUE +1
Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
InactiveUS6432699B1SsRNA viruses positive-senseGenetic material ingredientsGenetic MaterialsHuman cell
The invention involves viral vectors that can be used to transduce a target cell, i.e., to introduce genetic material into the cell. The targets of interest are eukaryotic cells and particularly human cells. The transduction can be done in vivo or in vitro. More particularly the invention concerns viral vectors that have chimeric envelope proteins and contain the IgG-binding domain of protein A. These vectors when used in conjunction with antibodies targeting a particular cell are particularly useful for gene therapy.
Owner:NEW YORK UNIV
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth.
Owner:CALIFORNIA INST OF TECH +1
Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (IFN) molecule attached to an antibody (Ab) which targets an antigen which is differentially expressed or up-regulated on activated T cells as compared to resting T cells, wherein the fusion molecule when contacted to an activated T cell results in induced apoptosis and programmed cell death or impairment of functions of said activated T cell.
Owner:IMMUNGENE
Targeting compounds
InactiveUS20130171074A1Increase in sizeExtended half-lifeUltrasonic/sonic/infrasonic diagnosticsAntibacterial agentsBinding siteBiological agent
The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.
Owner:THE SCRIPPS RES INST
Compositions and methods for antibodies targeting complement protein c3b
InactiveUS20100291106A1Low antigenicitySenses disorderSugar derivativesAntigen bindingAntibody targeting
Owner:NOVARTIS AG
Targeting interferon-lambda with antibodies potently enhances Anti-tumor and Anti-viral activities
ActiveUS20130136718A1Useful effectReduce amyloid plaqueMaterial nanotechnologyPeptide/protein ingredientsAntigen bindingAsthma
The present invention concerns methods and compositions for forming complexes of interferon-λ with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-λ and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis or viral infection than interferon-λ alone, antibody alone, or the combination of unconjugated interferon-λ and antibody.
Owner:IBC PHARMACEUTICALS INC
Compositions and methods for antibodies targeting epo
ActiveUS20140199306A1Prevent Epo bindingImprove acuitySenses disorderBacteriaAntigen Binding FragmentAntigen binding
Owner:NOVARTIS AG
Selective antibody targeting of undifferentiated stem cells
This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. The differentiated cell populations produced are suitable for use in tissue regeneration and non-therapeutic applications such as drug screening.
Owner:ASTERIAS BIOTHERAPEUTICS INC +1
ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
ActiveUS20100209428A1Inhibition of differentiationInhibition of maturationOrganic active ingredientsAntipyreticAntibody targetingFhit gene
Owner:DAIICHI SANKYO CO LTD
Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
Drug fusions and conjugates comprising an incretin therapeutic or diagnostic agent fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. Conjugates and fusions have longer half-lives in vivo compared to unconjugated or unfused therapeutic or diagnostic agents.
Owner:DORMANTIS LTD
Pharmaceutical composition for treatment and/or prophylaxis of cancer
ActiveUS9181334B2Treatment and/or prevention of cancerReduce usageImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCancer preventionComplementarity determining region
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and / or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and / or prevention of cancer, comprising the same as an active ingredient.
Owner:TORAY IND INC
Pharmaceutical composition for treatment and/or prophylaxis of cancer
ActiveUS20140186359A1Reduce usageUseful in treatmentSugar derivativesImmunoglobulins against cell receptors/antigens/surface-determinantsCancer preventionCancer cell
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and / or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and / or prevention of cancer comprising the same as an active ingredient.
Owner:TORAY IND INC
Pharmaceutical composition for treatment and/or prophylaxis of cancer
ActiveUS20140193434A1Reduce usageUseful in treatmentNervous disorderSugar derivativesCancer cellBULK ACTIVE INGREDIENT
It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and / or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising amino acid sequences of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and / or prevention of cancer, comprising this antibody or fragment as an active ingredient.
Owner:TORAY IND INC
Anti-tumor antibody compositions and methods of use
InactiveUS7435416B2Tumor rejection antigen precursorsCell receptors/surface-antigens/surface-determinantsTumor antigenAntibody targeting
The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.
Owner:GENENTECH INC
Anti-EDB antibody-targeted IL-10 cytokine for therapy of rheumatoid arthritis
InactiveUS8404814B2Improve stabilityHigh affinityPeptide/protein ingredientsAntipyreticOncofetal fibronectinRheumatoid arteritis
The present invention relates to fusion proteins comprising an antibody, functional fragment or functional derivative thereof having specific binding affinity to either the extracellular domain of oncofetal fibronectin (ED-B) or at least one of the extracellular domains of oncofetal tenascin fused to a cytokine selected from the group consisting of IL-10, IL15, IL-24 and GM-CSF, functional fragments and functional derivatives thereof. The invention is also directed to the use of at least one of said fusion proteins for the manufacture of a medicament. In particular, the invention concerns the use of said medicament for the treatment of tumors or chronic inflammatory diseases such as atherosclerosis, arthritis and psoriasis.
Owner:PHILOGEN SRL LLC
Compositions and methods for antibodies targeting bmp6
ActiveUS20160176956A1Reduced activityLow antigenicityPeptide/protein ingredientsImmunoglobulins against growth factorsAntigen Binding FragmentAntigen binding
The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.
Owner:NOVARTIS AG
Pharmaceutical composition for treatment and/or prophylaxis of cancer
ActiveUS20140154261A1Reduce usageUseful in treatmentSugar derivativesImmunoglobulins against cell receptors/antigens/surface-determinantsCancer cellBULK ACTIVE INGREDIENT
An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and / or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and / or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and / or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11.
Owner:TORAY IND INC
Pharmaceutical composition for treatment and/or prevention of cancer
ActiveUS20150044221A1Reduce usageUseful in treatmentSugar derivativesImmunoglobulins against animals/humansCancer preventionCancer cell
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and / or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and / or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient.
Owner:TORAY IND INC
Pharmaceutical composition for treatment and/or prophylaxis of cancer
ActiveUS20140178373A1Reduce usageUseful in treatmentNervous disorderSugar derivativesCancer preventionCancer cell
An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and / or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and / or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and / or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11.
Owner:TORAY IND INC
Pharmaceutical composition for treatment and/or prophylaxis of cancer
ActiveUS20140199311A1Treatment and/or prevention of cancerReduce usageSugar derivativesImmunoglobulins against cell receptors/antigens/surface-determinantsCancer preventionComplementarity determining region
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and / or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and / or prevention of cancer, comprising the same as an active ingredient.
Owner:TORAY IND INC
Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
An immuno-molecule which comprises a soluble human MHC class I effector domain; and an antibody targeting domain which is linked to the soluble human MHC class I effector domain, methods of making same and uses thereof.
Owner:TECHNION RES & DEV FOUND LTD
Treatment of tauopathies by passive immunization targeting the n-terminal projection domain of tau
ActiveUS20160102138A1Reducing tau levelDecreased tau hyperphosphorylatedImmunoglobulins against animals/humansAntibody ingredientsPassive ImmunizationsTau hyperphosphorylation
A method of treating tau pathologies, such as Alzheimer's disease, involving the administration of antibodies specific to the amino terminal region of human tau (amino acid residues 6-18 or 184-195) to provide passive immunization. The administration of such antibodies can reduce total tau levels, decrease tau hyperphosphorylation, and improve reference memory. Passive immunization with antibodies targeting the N-terminal projection domain of tau reduces both total and hyperphosphorylated tau was found effective in aged 3×Tg-AD mice, a generally accepted mouse model of Alzheimer's disease and frontotemporal dementia in humans.
Owner:RES FOUDATION FOR MENTAL HYGIENE INC
Blood-brain barrier targeting anti-bodies
This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis / transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and the antibody directs delivery of the compound across the blood brain barrier (BBB). The invention also provides methods of identifying endothelial cell specific antibodies by panning the library against cultured cell monolayers. The invention further allows for identifying endothelial cell receptors that bind the antibody thereby providing target receptors against which to isolate further cognate ligands and their associated transport systems and by which to identify transcytosis transporters targeted by the antibodies.
Owner:WISCONSIN ALUMNI RES FOUND
Methods and Systems for Predicting Response to Immunotherapies for Treatment of Cancer
ActiveUS20170168054A1Peptide/protein ingredientsBiological material analysisImmunotherapeutic agentCell membrane
A method of detecting cell membrane expression of an MHC molecule in a subject, a method of treating cancer in a subject with an immunotherapeutic agent, and an MHC complex are provided. The method of detecting cell membrane expression of an MHC molecule includes obtaining a tumor cell sample from a subject, and detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody. The method of treating cancer in a subject with an immunotherapeutic agent includes detecting cell membrane expression of an MHC molecule in the subject and administering a therapeutically effective amount of the immunotherapeutic agent if the level of cell membrane expression of the MHC molecule exceeds a predetermined standard. The complex includes a tumor cell in complex with an antibody or an antigen-binding portion thereof.
Owner:VANDERBILT UNIV
Pharmaceutical composition for treatment and/or prophylaxis of cancer
ActiveUS9180188B2Treatment and/or prevention of cancerReduce usageNervous disorderDigestive systemCancer cellHeavy chain
It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and / or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising amino acid sequences of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and / or prevention of cancer, comprising this antibody or fragment as an active ingredient.
Owner:TORAY IND INC
Immunogene therapeutic drug for chronic hepatitis B and preparation method for immunogene therapeutic drug
InactiveCN104940953AReduced viral copyImprove securityGenetic material ingredientsDigestive systemHBsAgChronic hepatitis
The invention relates to an immunogene therapeutic drug for chronic hepatitis B and a preparation method for the immunogene therapeutic drug. The active component of the drug is a replication-competent recombinant vector pSVK-dSFValpha-IRES-hIL-12 (for short, pSVK-HBVE), which is constructed by taking a pSVK carrier as a starting carrier and carries a fusion gene dSFValpha-IRES-hIL12. An antibody targeting interferon alpha and human IL-12 are co-expressed in the replication-competent recombinant vector pSVK to construct a humanized HBsAg dsFv antibody, human interferon-alpha and interleukin-12 fusion expression vector pSVK-dSFValpha-IRES-hIL-12, the fusion expression vector is efficiently expressed in an eukaryotic cell and in vitro, the combined application of human IL-12 and human IFN-alpha has an important synergistic effect during the tumor control process, and a safe and efficient immunogene therapeutic drug is provided for gene therapy of chronic hepatitis B.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Antibody targeting SARS-CoV-2 as well as preparation method and application of antibody
ActiveCN112390879ARandom combinationInhibit bindingAntibody mimetics/scaffoldsImmunoglobulins against virusesDiseaseImmune escape
The invention provides an antibody targeting SARS-CoV-2 and a preparation method and application thereof. The antibody comprises VH and VL, wherein the VH comprises the following CDRs: VH CDR1, VH CDR2 and VH CDR3 with amino acid sequences as shown in SEQ ID NO: 1, 2 and 3; the VL comprises the following CDRs: VL CDR1, VL CDR2 and VL CDR3 with amino acid sequences as shown in SEQ ID NO: 4, 5 and 6. The antibody can be highly compatible and specifically combined with RBD of S proteins of SARS-CoV-2, inhibits combination of the RBD protein and receptor ACE2 protein, efficiently inhibits SARS-CoV-2 from infecting cells, and has very good neutralizing activity on potential pseudoviruses of immune escape mutation, so that the antibody can be effectively applied to diagnosis, prevention and treatment of SARS-CoV-2 viruses and related diseases.
Owner:SHANGHAI TECH UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com